Succinylated Human Serum Albumin (Suc-HSA) for HIV-1 Infection
Information source: International Antiviral Therapy Evaluation Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: HIV Infections
Intervention: succinylated human serum albumin (Drug)
Phase: Phase 1/Phase 2
Status: Completed
Sponsored by: International Antiviral Therapy Evaluation Center Official(s) and/or principal investigator(s):
Joep MA Lange, MD PhD, Study Chair, Affiliation: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Jan Prins, MD PhD, Principal Investigator, Affiliation: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Summary
The primary objective of the study is to evaluate the pharmacokinetic behavior of Suc-HSA
after consecutive daily intravenous (i. v.) doses. The secondary objectives are to evaluate
the safety and tolerability and the antiretroviral and immunological effects of consecutive
daily i. v. doses of Suc-HSA.
Clinical Details
Official title: A Phase 1 & 2, Randomized Open-Label Study to Evaluate the Pharmacokinetics, Safety and Antiretroviral Activity of Succinylated Human Serum Albumin (Suc-HSA) in Treatment Naïve HIV-1 Infected Subjects
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: To evaluate the pharmacokinetic behavior of Suc-HSA after consecutive daily i.v. doses.
Secondary outcome: To evaluate the safety and tolerability and the antiretroviral and immunological effects of consecutive daily i.v. doses of Suc-HSA.
Detailed description:
This is a single centre, single arm study. Subjects will receive 5 consecutive daily doses
of Suc-HSA at a dose of 10 mg/kg on days 0, 1, 2, 3 and 4 on the Special Investigation Unit
(SIU), with a safety follow up on the SIU for 4 hours on day 1 and 2 hours on the next days.
There will be follow-up visits on week 1, 2, 4 and 12. Standard safety parameters (physical
examination, clinical symptoms, laboratory hematology and biochemistry) will be followed
until week 12. Plasma HIV-1 RNA and CD4+/CD8+ cell counts will be assessed at every visit.
Plasma drug levels (trough and peak) will be measured from baseline until week 2.
6 patients will be included in this study as described in this protocol amendment.
Eligible subjects are chronic HIV-1 infected patients who have never been treated with
antiretroviral treatment and for whom there is no need to start antiretroviral treatment.
Test Product: Suc-HSA, a candidate HIV-1 fusion inhibitor.
Duration of treatment: 5 days
Criteria for evaluation:
- Safety: symptoms, signs at physical examination, standard hematology and chemistry
laboratory parameters- Efficacy: changes in plasma HIV-1 RNA and CD4+ T cell count
- Pharmacokinetics: plasma levels of Suc-HSA: Cmin, Cmax and AUC
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Patient is ≥ 18 years of age;
2. Voluntarily signed informed consent;
3. Patient has a proven HIV-1 infection (with positive antibodies against HIV-1 and a
detectable plasma HIV-1 RNA);
4. Patient is HIV-1 treatment naïve;
5. CD4+ T-cell count ≥ 350 x 10^6/L;
6. Plasma HIV-1 RNA level at screening visit of at least 5. 000 copies/ml, and not
varying more than ± 0. 5 log10 copies during the preceding 6 month period;
7. Patient was participant in part 1 of the original Suc-HSA study (protocol no.
2003-002, version 2. 4, dated 18 November 2003) and the administration of Suc-HSA
occurred more than 8 weeks ago, OR patient was not participant in this study;
8. Patient is one of the following:
- not heterosexually active, OR
- a heterosexually active female, agreeing to use an effective method of
contraception with her partner (combined oral contraceptive pill; injectable
contraceptive; intrauterine contraceptive device (IUCD); consistent use of
condoms if using these; physiological or anatomical sterility in herself or her
partner) from 14 days prior to the first administration of study medication
until 4 months after the last, and willing to undergo urine pregnancy tests
prior to the first and last administration, OR
- a heterosexually active male, agreeing to use an effective method of
contraception with his partner from the day of the first administration until 4
months after the last administration.
Exclusion Criteria:
1. History of an AIDS defining event;
2. Use of antiretroviral or immunomodulatory therapy;
3. Any reason to start antiretroviral therapy at the time of enrolment or which is
expected to occur during the course of the study at the time of enrolment;
4. Presence of active, replicating hepatitis B and/or C virus co-infection;
5. ASAT and/or ALAT > 3 times upper limit of normal (ULN) (AIDS Clinical Trials Group
[ACTG] toxicity scale);
6. Serum creatinine measuring > 1. 5 x ULN;
7. Total bilirubin > 2x ULN;
8. Neutropenia (absolute neutrophil count < 1000/mm3);
9. Presence of any clinically significant disease or findings during screening, that in
the opinion of the investigator could compromise the safety of the subject;
10. Patient is female and (willing to become) pregnant or breast-feeding;
11. Any other condition which, in the opinion of the investigator, may interfere with the
evaluation of the study objectives.
Locations and Contacts
Academic Medical Center, University of Amsterdam, Amsterdam, NH 1105AZ, Netherlands
Additional Information
Starting date: August 2005
Last updated: April 23, 2007
|
